Evidence map›Paper›PMID 38110990›Full record

ArticleActa neuropathologica communications2023

Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain.

Vijay Singh, Marissa A Menard, Geidy E Serrano, Thomas G Beach, Hien T Zhao, Alexis Riley-DiPaolo, Nitya Subrahmanian, Matthew J LaVoie, Laura A Volpicelli-Daley

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. [MiRNA-103-3p promotes neural cell autophagy by activating Wnt/β-catenin signalingNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Vijay SinghCenter for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Marissa A MenardCenter for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Geidy E SerranoDepartment of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, 85351, USA.
Thomas G BeachDepartment of Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, 85351, USA.
Hien T ZhaoIonis Pharmaceuticals Inc, Carlsbad, CA, 92010, USA.
Alexis Riley-DiPaoloDepartment of Neuroscience at the University of Florida, Gainesville, FL, 32611, USA.
Nitya SubrahmanianDepartment of Neurology, Center for Translational Research in Neurodegenerative Disease, Fixel Institute for Neurologic Disease, University of Florida, Gainesville, FL, 32610, USA.
Matthew J LaVoieDepartment of Neurology, Center for Translational Research in Neurodegenerative Disease, Fixel Institute for Neurologic Disease, University of Florida, Gainesville, FL, 32610, USA.
Laura A Volpicelli-DaleyCenter for Neurodegeneration and Experimental Therapeutics, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. lvolpicellidaley@uabmc.edu.ORCID 0000-0001-8934-4018
University of Alabama at Birmingham · USUniversity of Florida · USBanner Sun Health Research Institute · USIonis Pharmaceuticals (United States) · US

Funding

Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI ALIREZA ATRI · 2021 to 2026
$24.9M
PATHOLOGIC LRRK2 SIGNALING IN FAMILIAL AND IDIOPATHIC PARKINSON'S DISEASER01NS110188 · NINDS · UNIVERSITY OF FLORIDA · PI LAVOIE, MATTHEW J · 2018 to 2022
$2.3M
Role of presynaptic targeting of alpha-synuclein in the pathogenesis of Parkinson's Disease and Dementia with Lewy BodiesR01NS102257 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VOLPICELLI-DALEY, LAURA A. · 2018 to 2022
$1.9M
Alpha-synuclein aggregate induced synapse loss is a pathological event contributing to Lewy body dementiasR56NS117465 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VOLPICELLI-DALEY, LAURA A. · 2020 to 2020
$769k
NIA NIH HHS P30 AG072980NINDS NIH HHS NIH RO1 NS102257NINDS NIH HHS R01 NS102257NINDS NIH HHS R01 NS110188NINDS NIH HHS R56 NS117465NINDS NIH HHS RO1 NS 110188NINDS NIH HHS RO1 NS 117465
6 · The paper itself

Abstract

Autosomal dominant pathogenic mutations in Leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease (PD). The most common mutation, G2019S-LRRK2, increases the kinase activity of LRRK2 causing hyper-phosphorylation of its substrates. One of these substrates, Rab10, is phosphorylated at a conserved Thr73 residue (pRab10), and is one of the most abundant LRRK2 Rab GTPases expressed in various tissues. The involvement of Rab10 in neurodegenerative disease, including both PD and Alzheimer's disease makes pinpointing the cellular and subcellular localization of Rab10 and pRab10 in the brain an important step in understanding its functional role, and how post-translational modifications could impact function. To establish the specificity of antibodies to the phosphorylated form of Rab10 (pRab10), Rab10 specific antisense oligonucleotides were intraventricularly injected into the brains of mice. Further, Rab10 knock out induced neurons, differentiated from human induced pluripotent stem cells were used to test the pRab10 antibody specificity. To amplify the weak immunofluorescence signal of pRab10, tyramide signal amplification was utilized. Rab10 and pRab10 were expressed in the cortex, striatum and the substantia nigra pars compacta. Immunofluorescence for pRab10 was increased in G2019S-LRRK2 knockin mice. Neurons, astrocytes, microglia and oligodendrocytes all showed Rab10 and pRab10 expression. While Rab10 colocalized with endoplasmic reticulum, lysosome and trans-Golgi network markers, pRab10 did not localize to these organelles. However, pRab10, did overlap with markers of the presynaptic terminal in both mouse and human cortex, including α-synuclein. Results from this study suggest Rab10 and pRab10 are expressed in all brain areas and cell types tested in this study, but pRab10 is enriched at the presynaptic terminal. As Rab10 is a LRRK2 kinase substrate, increased kinase activity of G2019S-LRRK2 in PD may affect Rab10 mediated membrane trafficking at the presynaptic terminal in neurons in disease.

Indexed as

Induced Pluripotent Stem CellsNeurodegenerative DiseasesParkinson DiseaseAnimalsBrainHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MiceMutationPhosphorylationrab GTP-Binding ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Rab10 protein, humanRab10 protein, mouserab GTP-Binding ProteinsAntisense oligonucleotideMouse brainParkinson’s diseasePhosphorylationpRab10Rab10Rab10 knock down

Identifiers

PMID38110990
PMCPMC10726543
OpenAlexW4389893996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.